Amicus Therapeutics Inc. (Nasdaq: FOLD) to submit a new drug application for its Fabry disease treatment migalastat in the fourth quarter sending the stock price soaring $2.66 to close at $12.92.
Amicus Therapeutics to submit NDA for migalastat
July 11, 2017 at 16:51 PM EDT
